Takeda hoping for third time lucky as it resubmits alogliptin and combo in US
This article was originally published in Scrip
Takeda has re-filed new drug applications in the US for its antidiabetic alogliptin and a fixed-dose combination of the dipeptidyl peptidase IV inhibitor with pioglitazone (Takeda's Actos), hoping that this time it will be able to satisfy the agency's concerns after years of delays.
You may also be interested in...
Positive clinical results in Parkinson’s pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.